0001193125-22-274030.txt : 20221031 0001193125-22-274030.hdr.sgml : 20221031 20221031170030 ACCESSION NUMBER: 0001193125-22-274030 CONFORMED SUBMISSION TYPE: DEFA14A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20221031 DATE AS OF CHANGE: 20221031 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ACORDA THERAPEUTICS INC CENTRAL INDEX KEY: 0001008848 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEFA14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-31938 FILM NUMBER: 221346892 BUSINESS ADDRESS: STREET 1: 420 SAW MILL RIVER ROAD CITY: ARDSLEY STATE: NY ZIP: 10502 BUSINESS PHONE: 914-347-4300 MAIL ADDRESS: STREET 1: 420 SAW MILL RIVER ROAD CITY: ARDSLEY STATE: NY ZIP: 10502 DEFA14A 1 d306439ddefa14a.htm DEFA14A DEFA14A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.     )

 

 

Filed by the Registrant  ☒

Filed by a Party other than the Registrant  ☐

Check the appropriate box:

 

Preliminary Proxy Statement

 

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

Definitive Proxy Statement

 

Definitive Additional Materials

 

Soliciting Material under §240.14a-12

ACORDA THERAPEUTICS, INC.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply):

 

No fee required.

 

Fee paid previously with preliminary materials.

 

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 


LOGO

Special Meeting November 4.

We need your vote.

Please ensure your voice is heard by voting today.

Dear Acorda stockholder:

The special meeting of Acorda stockholders is this Friday, November 4, 2022. The time to vote is NOW! Please vote your shares today!

Support Acorda’s Business Plan

Your Board of Directors, ISS and Glass Lewis, all recommend that you vote “FOR” the Reverse Stock Split (proposal 2). Approval of the Reverse Stock Split proposal is key to Acorda’s ability to execute its business plan.

Acorda issued a press release on October 27, 2022 on its long-term business plan and financial guidance through 2027, which we encourage you to review prior to your vote at the special meeting.

Acorda has developed a long-term business plan to increase the value of the Company, focused on growing INBRIJA® (levodopa inhalation powder), maximizing AMPYRA® (dalfampridine), and implementing additional operational and manufacturing efficiencies. Acorda has substantial liquidity which the Company expects will allow it to execute on this business plan.

Your vote is critically important. Please vote today. Vote FOR approval of the Reverse Split proposal to support execution of Acorda’s long-term business plan.

Internet voting and voting by the QR code you received are the quickest ways to vote. Otherwise please contact D.F. King for assistance voting your shares at 1-800-967-5051 or via email at ACOR@dfking.com.

How Shareholders Can Vote:

You are encouraged to cast your vote promptly “FOR” the Reverse Stock Split proposal without further delay.


Online: www.proxyvote.com Please have the control number that was sent to you in the mail.

By QR Code: Please vote using the QR code you received by email or on the voting instruction form.

By phone: Call 1-800-967-5051, Monday—this Thursday 9am—10pm ET only.

Mail: Sign, date, and return your proxy card in the postage-paid, stamped envelope provided, but make sure your vote is delivered by Thursday of this week.

GRAPHIC 2 g306439g1031222213986.jpg GRAPHIC begin 644 g306439g1031222213986.jpg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end